As the COVID-19 pandemic began to wreak havoc on the world in 2020, the biopharmaceutical industry started working tirelessly to develop a vaccine to stop this global threat. Emerging from this effort ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

A new synthesis method offers hope for creation of advance mRNA vaccines to fight viruses and even cancers. Researchers at Nagoya University in Japan have developed a new chemical-only process that ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...

Vaccines to prevent SARS-CoV-2 infection were not the first attempt at utilizing the promise of mRNA in a therapeutic setting. From the discovery of mRNA in the 1960s, many scientists, clinicians, and ...

mRNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

Developers of mRNA therapeutics face an increasingly complex landscape: rising expectations for potency and durability, ...

Stanford Medicine investigators have unearthed the biological process by which mRNA-based vaccines for COVID-19 can cause ...

STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA ...